Praecis Puts Brakes On Plenaxis, Explores Strategic Financing Options

Company will record $7.5 mil. in charges after announcing it will not enter a licensing or sale transaction for the prostate cancer therapy.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet